相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pneumonitis as A Consequence of (Peg)Interferon-Ribavirin Combination Therapy for Hepatitis C: a Review of the Literature
Serena Slavenburg et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha for Chronic Hepatitis C
Sonu Dhillon et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy-A Genome-Wide Study of Japanese HCV Virus Patients
Hidenori Ochi et al.
GASTROENTEROLOGY (2010)
Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
Risk Factors for Infection During Treatment with Peginterferon alfa and Ribavirin for Chronic Hepatitis C
Robert Roomer et al.
HEPATOLOGY (2010)
Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
Robert Roomer et al.
JOURNAL OF HEPATOLOGY (2010)
ELTROMBOPAG IN CHRONIC LIVER DISEASE PATIENTS WITH THROMBOCYTOPENIA UNDERGOING AN ELECTIVE INVASIVE PROCEDURE: RESULTS FROM ELEVATE, A RANDOMISED CLINICAL TRIAL
N. Afdhal et al.
JOURNAL OF HEPATOLOGY (2010)
Use of Epoetin Beta During Combination Therapy of Infection With Hepatitis C Virus With Ribavirin Improves a Sustained Viral Response
Katia Falasca et al.
JOURNAL OF MEDICAL VIROLOGY (2010)
Ophthalmologic Complications in Children With Chronic Hepatitis C Treated With Pegylated Interferon
Michael R. Narkewicz et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2010)
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
Jacques Fellay et al.
NATURE (2010)
Pegylated-Interferon-Associated Retinopathy in Chronic Hepatitis Patients
Ji Won Lim et al.
OPHTHALMOLOGICA (2010)
Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia
Marilyn Huckans et al.
SCHIZOPHRENIA BULLETIN (2010)
Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice
J. -F. Yang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Treatment of erythrodermic psoriasis in HCV plus patient with adalimumab
Antonio Giovanni Richetta et al.
DERMATOLOGIC THERAPY (2009)
Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin
Soraya de Mattos Camargo Grossmann et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
Decline in Male Sexual Desire, Function, and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C
Lorna M. Dove et al.
GASTROENTEROLOGY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin
Ei Tae Kim et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2009)
Ribavirin: Current role in the optimal clinical management of chronic hepatitis C
K. Rajender Reddy et al.
JOURNAL OF HEPATOLOGY (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C
T. -M. Scherzer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus
Cecilia T. Costiniuk et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2008)
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin
M. G. Antonini et al.
INFECTION (2008)
High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection
Tim C. M. A. Schreuder et al.
LIVER INTERNATIONAL (2008)
Interferon alpha treatment and thyroid dysfunction
Yaron Tomer et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2007)
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hepatitis C treatment in Difficult-to-Treat psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects
Martin Schaefer et al.
HEPATOLOGY (2007)
Reversible alopecia universalis secondary to PEG-interferon α-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection
Elif Doyuk Kartal et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2007)
Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C
Alper Yurci et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2007)
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
Mitchell L. Shiffman et al.
HEPATOLOGY (2007)
Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus
Yuki Hashimoto et al.
JOURNAL OF DERMATOLOGY (2007)
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
Mitchell L. Shiffman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Modafinil's use in combating interferon-induced fatigue
Kari A. Martin et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment
K. Rajender Reddy et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
The 5-HT3 receptor as a therapeutic target
Andrew J. Thompson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon
Bart J. Veldt et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2007)
Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis - A long-term followup study
David Saadoun et al.
ARTHRITIS AND RHEUMATISM (2006)
Sarcoidosis after treatment with interferon-α:: A case series and review of the literature
Hilary J. Goldberg et al.
RESPIRATORY MEDICINE (2006)
Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia
Curtis L. Cooper et al.
HIV CLINICAL TRIALS (2006)
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
Hari S. Conjeevaram et al.
GASTROENTEROLOGY (2006)
Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia
Curtis L. Cooper et al.
CLINICAL INFECTIOUS DISEASES (2006)
Hepatitis C treatment for people with severe mental illness
LA Mistler et al.
PSYCHOSOMATICS (2006)
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders
S Chainuvati et al.
JOURNAL OF VIRAL HEPATITIS (2006)
Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C
Bertrand Condat et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2006)
Chronic hepatitis C and Crohn's disease: Nosocomial infection treatment with PEG-interferon plus ribavirin
Xamila Salcedo-Mora et al.
DIGESTION (2006)
Side effects of interferon-α therapy
S Sleijfer et al.
PHARMACY WORLD & SCIENCE (2005)
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: Evidence for an overlap between manic/hypomanic and depressive symptoms
A Constant et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens
M Schmid et al.
GUT (2005)
Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C - A case report and review of the literature
EA Hurst et al.
ARCHIVES OF DERMATOLOGY (2005)
Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C
TB Niewold et al.
CLINICAL RHEUMATOLOGY (2005)
Depression during therapy with interferon α -: How long should an antidepressant treatment last?: A case report
T Nickel et al.
PHARMACOPSYCHIATRY (2005)
Neuropsychiatric adverse effects of interferon-alpha - Recognition and management
CL Raison et al.
CNS DRUGS (2005)
Generalised dermatitis induced by pegylated interferion-alpha-2b in a patient infected with genotype-1 hepatitis C virus - Presentation of a case
L Gallelli et al.
CLINICAL DRUG INVESTIGATION (2005)
Global epidemiology of hepatitis C virus infection
CW Shepard et al.
LANCET INFECTIOUS DISEASES (2005)
Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study
NH Afdhal et al.
GASTROENTEROLOGY (2004)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Is screening for interferon retinopathy in hepatitis C justified?
FM Cuthbertson et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2004)
Hepatocellular carcinoma: Recent trends in the United States
HB El-Serag
GASTROENTEROLOGY (2004)
Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: A 6-year follow-up study
H Kanazawa et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Colonic toxicity of administered drugs and chemicals
MS Cappell
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection
MS Sulkowski et al.
JOURNAL OF VIRAL HEPATITIS (2004)
Review article: type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy
P Fabris et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Interferon-α and autoimmune thyroid disease
MF Prummel et al.
THYROID (2003)
Hepatitis C virus and arthritis
I Olivieri et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2003)
Autoimmune disease complicating antiviral therapy for hepatitis C virus infection
LE Wilson et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2002)
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
A Soza et al.
HEPATOLOGY (2002)
Adherence to combination therapy enhances sustained response in genotyp-1-infected patients with chronic hepatitis C
JG McHutchison et al.
GASTROENTEROLOGY (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study
G Mazziotti et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2002)
Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C
J Wendling et al.
ARCHIVES OF DERMATOLOGY (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Tolerability of treatments for viral hepatitis
A Gervais et al.
DRUG SAFETY (2001)
The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985
TT Yee et al.
GUT (2000)
分享论文
